An interventional study of ctDNA in Breast Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 13 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust — 5 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 15 with no phase, and was the 35th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 3
First in 1997; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 62 across the 24 interventional studies, 150 across the 12 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
3 of the studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04920708Royal Marsden NHS Foundation TrustFulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | 2027-06 |
| NCT04360941Royal Marsden NHS Foundation TrustPAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | 2027-07-31 |
| NCT04985266Royal Marsden NHS Foundation TrustA Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery. The study includes patients with stage I HER2-positive breast cancer and patients with stage I triple-negative breast cancer (TNBC) with high levels of tumour-infiltrating lymphocytes (TILs). The Signatera personalised ctDNA assay is used to detect molecular residual disease (MRD), which may indicate that cancer remains in the body after surgery.
SAFE-DE comprises two parts. Part A, which is closed to recruitment, investigated the incidence of post-operative ctDNA detection and its association with subsequent outcomes, including the potential prognostic significance of pre-operative ctDNA. Part B builds on this work by prospectively evaluating whether ctDNA-guided treatment and surveillance can reduce the use of adjuvant chemotherapy while maintaining favourable cancer outcomes.
Patients may be enrolled before surgery to facilitate pre-operative sampling and timely post-operative testing. Blood samples will be collected after surgery, including at 2 and 4 weeks. The results of the 2- and 4-week post-operative ctDNA tests will be shared with patients and their treating clinicians to inform treatment decisions in accordance with the study protocol and individual clinical circumstances. Pre-operative ctDNA results will be investigated as an exploratory measure and will not be disclosed for treatment decisions.
Patients with detectable ctDNA after surgery will be recommended standard adjuvant systemic treatment. Patients with no detectable ctDNA at both 2 and 4 weeks after surgery will be recommended not to receive adjuvant chemotherapy and will instead enter a ctDNA surveillance programme. If ctDNA becomes detectable during surveillance, patients will then be offered standard adjuvant treatment.
The primary purpose of Part B is to assess whether patients with undetectable ctDNA following surgery can remain free from distant recurrence without adjuvant chemotherapy. Additional outcomes include recurrence and survival, adjuvant treatment use, ctDNA detection during surveillance, quality of life and the cost-effectiveness of ctDNA-guided treatment.
Patients with stage I breast cancer generally have a favourable prognosis following surgery. However, patients with stage I HER2-positive breast cancer and triple-negative breast cancer (TNBC) remain at risk of recurrence and are commonly offered adjuvant systemic treatment following surgery. Although shorter chemotherapy regimens are used to reduce treatment-related morbidity, some patients may remain disease-free without chemotherapy, while others have residual cancer after surgery and remain at risk of recurrence despite treatment. Identifying patients who can safely avoid adjuvant chemotherapy, while ensuring that those at increased risk receive appropriate treatment, remains an important clinical challenge.
Circulating tumour DNA (ctDNA) provides a potential means of detecting molecular residual disease (MRD), which refers to cancer that remains in the body following treatment but may not be detectable using conventional clinical assessments. As tumour cells proliferate and die, tumour-derived DNA can be released into the circulation. Sequencing a patient's tumour to identify tumour-specific alterations enables highly sensitive analysis of plasma DNA for these alterations. Detection of ctDNA following potentially curative treatment is associated with an increased risk of subsequent disease recurrence.
The SAFE-DE study uses the Signatera personalised ctDNA assay to investigate the role of ctDNA testing in patients with stage I HER2-positive breast cancer and stage I TNBC with high levels of tumour-infiltrating lymphocytes (TILs). The study comprises two parts.
Part A, which is closed to recruitment, investigated the incidence of ctDNA detection in patients with stage I HER2-positive and triple-negative breast cancer following surgery. Its purpose was to identify patients with evidence of molecular residual disease and investigate the association between ctDNA detection and subsequent outcomes. The study also explored pre-operative ctDNA detection as a potential prognostic measure. Pre-operative results were not disclosed to patients or treating clinicians for treatment decisions because their clinical significance was less established than that of post-operative ctDNA detection.
Part A provided the foundation for the next stage of the study by investigating the use of ctDNA testing to identify patients who may be at increased risk of recurrence following surgery.
Part B builds on Part A by prospectively evaluating whether post-operative ctDNA results can be used to guide adjuvant treatment decisions, with the aim of reducing unnecessary chemotherapy while maintaining favourable cancer outcomes.
Patients may be enrolled before surgery to facilitate collection of pre-operative samples and timely post-operative testing. Pre-operative ctDNA will be investigated as an exploratory measure, and results will not be made available to patients or their treating clinicians for treatment decisions.
Following surgery, blood samples will be collected for ctDNA testing, including at 2 and 4 weeks after surgery. The results of these post-operative tests will be shared with patients and their treating clinicians and used to guide treatment in accordance with the study protocol.
Patients with detectable ctDNA after surgery will receive standard adjuvant systemic treatment, reflecting the increased risk of recurrence associated with molecular residual disease.
Patients with no detectable ctDNA at both 2 and 4 weeks after surgery will be recommended not to receive adjuvant chemotherapy and will instead enter a ctDNA surveillance programme. Serial blood testing during follow-up will allow the study to assess whether ctDNA remains undetectable or becomes detectable over time. If ctDNA becomes detectable during surveillance, patients will be offered standard adjuvant treatment.
The primary purpose of Part B is to determine whether patients with undetectable ctDNA following surgery can remain free from distant recurrence without receiving adjuvant chemotherapy. The study will also assess other measures of recurrence and survival, patterns of anticancer treatment use, ctDNA detection during surveillance, quality of life and the cost-effectiveness of using ctDNA to guide treatment decisions.
By evaluating a ctDNA-guided treatment and surveillance strategy, SAFE-DE aims to provide further evidence on whether molecular residual disease testing can support more personalised management of early breast cancer, reducing exposure to chemotherapy in selected patients while identifying those who may require additional treatment.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed breast cancer that is either:
(A) -positive as defined by 2023 ASCO-CAP guidelines determined by local testing* or (B) Triple negative defined as ER negative (ER staining in \<1% tumour cells or ER Allred score \<3/8) and PR negative (PR staining in \<10% tumour cells or PR Allred score \<6/8) and HER2-negative by 2023 ASCO-CAP guidelines determined by local testing. Patients without PR testing results may enrol on the basis of ER and HER2 results.
* Note: Patients negative for ER and PR may enrol whilst awaiting HER2 testing results
Pathological stage 1 cancer as below: **
EITHER
AND (c) Node negative (isolated tumour cells are allowed)
**Patients may be enrolled pre-operatively with clinical stage 1 cancer with primary tumour size on imaging 5-20mm and a normal axilla ultrasound or a negative axilla. Patients enrolled before surgery will only continue in study after surgery when confirmed pathological stage 1
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants
Diagnostic Test: ctDNA
Patients with stage 1 HER2-positive breast cancer or stage 1 triple-negative breast cancer (TNBC) with high tumour infiltrating lymphocytes (TILs) will have access to the Signatera genome ctDNA assay alongside standard clinical care. Patients will preferably be enrolled prior to surgery and will have ctDNA testing before and after surgery. The pre-surgery ctDNA result will not be made available to patients or their treating clinicians. Post-surgery ctDNA results will be made available to treating clinicians and will be used to inform clinical decision-making regarding adjuvant systemic treatment. Patients with undetectable ctDNA after surgery may be managed without adjuvant chemotherapy and will undergo further ctDNA surveillance instead. Patients with detectable ctDNA after surgery, who are considered to have a higher risk of relapse, will not enter the surveillance population in which adjuvant systemic treatment is omitted.
Distant recurrence-free interval in patients with undetectable post-surgery ctDNA
The time from the date of surgery to the first recorded event of distant recurrence or death from breast cancer. This will be evaluated in patients who proceed to surgery and have at least one undetectable ctDNA result at either 2 and/or 4 weeks post-surgery, with no detected ctDNA result at either post-surgery timepoint. Patients without a recorded event will be censored at the first occurrence of death from another cause, complete withdrawal from trial follow-up, or diagnosis of a new primary cancer. This will be assessed separately in patients with stage 1 HER2-positive breast cancer and patients with stage 1 TNBC with high tumour infiltrating lymphocytes (TILs).
Time frame: From the date of surgery until first documented event, assessed up to 10 years.
Distant recurrence-free interval in all patients
The time from the date of surgery to the first recorded event of distant recurrence or death from breast cancer, evaluated in all patients who proceed to surgery regardless of their ctDNA status at 2 and 4 weeks post-surgery. Results will be reported in the HER2-positive cohort, TNBC cohort, and both cohorts combined.
Time frame: From the date of surgery until first documented event, assessed up to 10 years.
Invasive disease-free survival (IDFS)
The time from the date of surgery to the first occurrence of an invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death from another cause, death from an unknown cause, invasive contralateral breast cancer, or a second primary invasive cancer (non-breast). This will be evaluated in patients with undetectable ctDNA MRD following surgery.
Time frame: From the date of surgery until first documented event, assessed up to 10 years.
Recurrence-free interval (RFI)
The time from the date of surgery to the first occurrence of an invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, or death from breast cancer. This will be evaluated in patients with undetectable ctDNA MRD following surgery.
Time frame: From the date of surgery until first documented event, assessed up to 10 years.
Distant recurrence-free survival (DRFS)
The time from the date of surgery to the first occurrence of distant recurrence or death from breast cancer. This will be evaluated in patients with undetectable ctDNA MRD following surgery.
Time frame: From the date of surgery until first documented event, assessed up to 10 years.
Breast cancer-specific survival (BCSS)
The time from the date of surgery to death from breast cancer. This will be evaluated in patients with undetectable ctDNA MRD following surgery.
Time frame: From the date of surgery until documented date of death from breast cancer, assessed up to 10 years.
Overall survival (OS)
The time from the date of surgery to death from any cause. This will be evaluated in patients with undetectable ctDNA MRD following surgery.
Time frame: From the date of surgery until date of death, assessed up to 10 years.
Started Jun 2023 (actual). Primary completion is estimated for Jan 2038, 174 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 174 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2025 → Jan 2038 and completion Dec 2028 → Jan 2038.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →